A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis

A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic Fibrosis

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have any action).

Inclusion Criteria:

• Male or post-menopausal or surgically sterile female patients
• Have a clinical diagnosis of Cystic Fibrosis with lung function tests greater or equal to 40% of normal
• Have normal renal function

Exclusion Criteria:

• Lung transplant patients
• Significant liver disease
• Any other non-CF-related lung disease that may interfere with study assessments